Glucoplus (Metformin Hydrochloride)

Glucoplus is indicated for the management of hyperglycemia in patients with type 2 diabetes mellitus, typically as part of a comprehensive treatment plan that includes diet and exercise.

• As monotherapy in patients newly diagnosed with type 2 diabetes when diet and exercise alone are insufficient.
• In combination with other oral antidiabetic agents (e.g., sulfonylureas, DPP‑4 inhibitors) to achieve additional glycemic control.
• As adjunct therapy with insulin to reduce insulin dose requirements.
• For patients with overweight or obesity where metformin’s weight‑neutral or modest weight‑loss effect is beneficial.

Like other metformin products, Glucoplus may cause a range of adverse effects. Most are mild and transient, such as gastrointestinal symptoms, while rare serious reactions require prompt medical attention.

Common

• Gastrointestinal upset such as nausea, abdominal discomfort, or diarrhea.
• Metallic taste in the mouth.
• Decreased appetite.
• Mild headache.
• Transient dizziness or light‑headedness.

Serious

• Lactic acidosis, a rare but potentially fatal metabolic complication.
• Severe skin reactions including Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Persistent vomiting leading to dehydration.
• Hypersensitivity reactions such as rash or pruritus.

Healthcare providers should evaluate several factors before prescribing Glucoplus to ensure safe and effective use.

• Assess renal function; metformin is contraindicated in severe renal impairment.
• Monitor liver function, as hepatic disease may increase risk of lactic acidosis.
• Use caution in patients with heart failure or a history of hypoxia.
• Adjust dose or discontinue before any radiologic procedures that use iodinated contrast agents.
• Review pregnancy and lactation status; metformin is generally avoided unless benefits outweigh risks.
• Evaluate for alcohol abuse, which can potentiate lactic acidosis.
• Consider age‑related changes in renal clearance when dosing older adults.

Glucoplus can interact with several medications, affecting its efficacy or safety profile.

Avoid

• Iodinated contrast media administered intra‑arterially or intravenously.
• Cimetidine, which can increase metformin plasma concentrations.
• Certain antiretroviral drugs (e.g., didanosine) that raise the risk of lactic acidosis.
• Trimethoprim, which may increase metformin concentrations.

Use with caution

• Diuretics that may affect renal function.
• ACE inhibitors or ARBs in patients with compromised kidney function.
• Alcohol consumption, which can predispose to metabolic acidosis.
• Beta‑blockers, as they can mask hypoglycemia symptoms.
• Other antihypertensive agents that may influence renal perfusion.